Researchers Focus on Innovations for Digital Device Users and Presbyopes
ROCHESTER, N.Y., January 15, 2025—Two scientific posters presented at this week’s 2025 Global Contact Lens Symposium (GSLS) reveal new research surrounding CooperVision advancements that are shaping the contact lens category. They profile aspects of the unique optical design used in MyDay Energys® and Biofinity Energys® brands for digital device users, as well as the company’s innovative Binocular Progressive System™ for presbyopes that is part of the MyDay® and clariti® 1 day product families.
“While we conduct and support a sizable range of foundational studies every year, we also prioritize research that helps eye care professionals (ECPs) have a deeper understanding of how the contact lenses they fit everyday work in practice on their patients. This helps support confidence among prescribers, ideal patient experiences, and practice success. It’s the type of practical scientific evidence that the profession has come to expect from a partner like CooperVision,” said Francis Erard, the company’s Vice President of Research & Development.
CooperVision designed DigitalBoost™ Technology to help with eye tiredness associated with digital device use by delivering a +0.3D boost in an innovative single vision aspheric lens design.*1,2 The authors of Performance of Two Contact Lens Designs in a Clinical Setting and Through Computational Optical Modelling (Walsh K, et al) examined two aspects of MyDay Energys® performance, both of which help account for the popularity of that lens as well as Biofinity Energys®.
A team from the Centre for Ocular Research & Education (CORE) at the University of Waterloo evaluated distance visual acuity (VA) and subjective responses among 77 subjects in a multi-center, bilateral wear, one-week dispensing study. Compared to MyDay® sphere, there was no difference in binocular logMAR high contrast distance VA with MyDay Energys®. In addition, MyDay Energys® was rated more comfortable than MyDay® sphere on average, with notable end-of-day differences favoring MyDay Energys®.
In parallel, a team from the James C. Wyant College of Optical Sciences at the University of Arizona used computational optical modelling to visualize the image quality between the two lens designs at different vergences. Three-dimensional scene analysis showed better image quality at near and intermediate distances for MyDay Energys® compared to MyDay® sphere, with similar distance image quality.
Since dioptric power changes across multifocal contact lens optic zones create simultaneous foci that reduce contrast and affect perceived vision quality, researchers sought to assess the associated impact of pupil size which varies by individual and under different luminance levels.
Influence of Pupil Size on Vision Performance and Visual Satisfaction with a Daily Disposable Multifocal Contact Lens System (Marullo R, et al) enrolled 45 presbyopes with varied pupil sizes (2.3 mm at 250cd/m2 to 6.6 mm at 2.5cd/m2) fit into MyDay® daily disposable multifocal with the Binocular Progressive System™ contact lenses. Investigators measured distance binocular high contrast visual acuity (BHCVA) under high and low illumination, distance binocular low contrast visual acuity (BLCVA) under high illumination, near BHCVA and near BHLCA under medium illumination, as well as subjective vision satisfaction scores at distance and near. No significant correlations were found between visual acuity and pupil size regardless of viewing distance, contrast, and luminance. Correlations between vision metrics (visual acuity and vision satisfaction) and pupil size after one week of wear were weak or very weak in every environmental condition. The findings indicate that the Binocular Progressive System™ effectively corrects for presbyopia independent of pupil size, supporting that the latest MyDay® multifocal and clariti® 1 day multifocal offerings give ECPs the ability to fit a wide spectrum of patients.
During GSLS, CooperVision is also sharing analysis of real world retrospective axial length (AL) data from 429 patients ages 6-19 years who wore overnight orthokeratology contact lenses (Paragon CRT® 100 and Paragon CRT Dual Axis®,) at the Berkeley Myopia Control Clinic between 2008 and 2023. Comparison of Axial Eye Growth in Children Undergoing Orthokeratology to Myopic Eye Growth (Hammond D, et al) found that eye growth among these patients was slower than expected if left untreated, with rates approximately half compared to anticipated progression in adolescent eyes (11-18) and slightly greater than 50% in younger eyes (6-10). The Paragon CRT® 100 and Paragon CRT Dual Axis® lens treatment effects were similar.
“The caliber of eye care is constantly increasing around the globe, as are expectations among patients and ECPs alike. CooperVision believes that reinforcing everyday clinical decisions with sound evidence will continue to become more critical, and why we are dedicated to advancing ocular science through the research we conduct and support though our partnerships,” said Erard.
A full schedule of events and presentations for GSLS 2025, which takes place in Las Vegas from January 15-18, 2025, is available at gslsymposium.com.
###
Footnotes:
*Based on a statistically significant difference of the mean change in Accommodative Microfluctuations and when compared to a lens without DigitalBoost™ after reading on an iPhone 5 for 20 minutes held at a distance of 25 cm. Study conducted with Biofinity Energys and sphere.
References:
1. CVI data on file, 2024.
2. Kajita M et al. Changes in accommodative micro-fluctuations after wearing contact lenses of different optical designs. CLAE 2020; 43(5): 493-496.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week, and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, visit www.coopercos.com.
Media Contact
Mike McDougall, APR, Fellow PRSA, FAAO
McDougall Communications for CooperVision
mike@mcdougallpr.com or +1.585.545.1815